Teva Pharmaceutical Industries (TEVA.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec10

Teva Pharmaceuticals Removes Over 200 Improper Patents Under FTC Pressure

16:51

Menora Mivtachim Holdings Increases Teva Pharmaceutical Holdings

12:59

Dec9

Teva Pharmaceuticals Submits New Drug Application for Long-Acting Olanzapine Injection to FDA

13:00

FactSet: Teva Pharmaceutical's Target Price Raised to $31

12:17

Bank of America Securities Reiterates Buy Rating on Teva, Barclays Joins Coverage

10:42

Dec1

Roberto Mignone Disposes of Teva Pharmaceutical Ordinary Shares

21:03

Schedules & Filings

Schedules

Filings

Nov5

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 4.48 B, Net Income 433 M, EPS 0.37

Jul30

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 4.176 B, Net Income 282 M, EPS 0.24

May7

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 3.891 B, Net Income 214 M, EPS 0.18

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change